Patient: BILAL, MUHAMMAD SAQIB Lab No: 2026-6B7181458
Reference #:
Age: 40 years Sex: M Patient ID: 20266B7181458
Date of Birth: Dec 04 1985 Referring Site ID:
Address: 100 International Blvd.
HC #: 3072320983 HG Toronto, Ontario
Canada M9W 6J6
Patient's Phone: (647) 864-1186 Date of Service: Apr 28 2026 14:20
Telephone: (877) 849-3637
Reported on: Apr 29 2026 07:03 Toll Free: (877) 849-3637
Ordered by: PARVEEN DR. SAYEMA Fax: (905) 795-9891
Copy To:
Test Flag Result Reference Range - Units Lab Lic. #
Hematology
#5687
WBC 7.7 4.0 - 11.0 x E9/L
RBC 5.85 4.50 - 6.00 x E12/L
Hemoglobin 168 135 - 175 g/L
Hematocrit 0.487 0.400 - 0.500 L/L
MCV 83 80 - 100 fL
MCH 28.7 27.5 - 33.0 pg
MCHC 345 305 - 360 g/L
RDW 11.9 11.5 - 14.5 %
Platelet Count 268 150 - 400 x E9/L
Differential
Neutrophils 4.0 2.0 - 7.5 x E9/L
Lymphocytes 2.7 1.0 - 3.5 x E9/L
Monocytes 0.5 0.2 - 1.0 x E9/L
Eosinophils 0.4 0.0 - 0.5 x E9/L
Basophils 0.1 0.0 - 0.2 x E9/L
Immature Granulocytes 0.0 0.0 - 0.1 x E9/L
Nucleated RBC 0 /100 WBC
Biochemical Investigation of Anemias
Vitamin B12 Results are pending ...
#5407
Ferritin 285 ug/L
In absence of concomitant inflammation, Ferritin
levels can be interpreted as follows:
30-50 ug/L: Probable iron deficiency
51-100 ug/L: Possible iron deficiency, if risk
factors are present
101-300 ug/L: Iron deficiency unlikely
=>600 ug/L: Consider test for iron overload
In patients with concomitant inflammation, use
Iron Studies, including TIBC and Transferrin
Saturation, to assess Iron Deficiency status.
For guidance, see [Link]/raise-the-bar
General Chemistry
#5687
Hemoglobin A1C/Total Hemoglobin 5.9 <6.0 %
Diabetes Canada 2018 Guidelines:
Lab - 5407: KENNEDY, 6560 Kennedy Road, Mississauga, Ontario.
Lab - 5687: LifeLabs, 100 International Blvd., Toronto, Ontario.
Page 1 of 3
PARTIAL RESULTS
IMPORTANT: This report contains confidential information intended for view by authorized person(s) only and should be
disposed of securely (e.g. shredding) before discarding.
Note to Health Care Providers: This report has been printed by the patient.
Note to patients: Please contact your Health Care Provider if you have any questions regarding the results on this report.
Patient: BILAL, MUHAMMAD SAQIB Lab No: 2026-6B7181458
Reference #:
Age: 40 years Sex: M Patient ID: 20266B7181458
Date of Birth: Dec 04 1985 Referring Site ID:
Address: 100 International Blvd.
HC #: 3072320983 HG Toronto, Ontario
Canada M9W 6J6
Patient's Phone: (647) 864-1186 Date of Service: Apr 28 2026 14:20
Telephone: (877) 849-3637
Reported on: Apr 29 2026 07:03 Toll Free: (877) 849-3637
Ordered by: PARVEEN DR. SAYEMA Fax: (905) 795-9891
Copy To:
Test Flag Result Reference Range - Units Lab Lic. #
General Chemistry
#5687
--------------------------------------------------
Screening and Diagnosis:
< 5.5 % Normal
5.5% - 5.9 % At risk
6.0% - 6.4 % Prediabetes
>OR= 6.5 % Diabetes Mellitus***
***Regarding diagnosis: in the absence of
symptomatic hyperglycemia, if a single laboratory
test result is in the diabetes range, a repeat
confirmatory laboratory test (FPG, A1C, 2hPG in a
75 g OGTT) must be done on another day for
diagnosis confirmation.
--------------------------------------------------
Monitoring: <OR= 7.0 %
Target in adults without comorbidities. Other
targets may be more appropriate in children,
elderly and patients with comorbidities.
--------------------------------------------------
Results may not accurately reflect mean blood
glucose in patients with hemoglobin variants,
disorders associated with abnormal erythrocyte
turnover, severe renal and liver disorders.
#5407
Sodium 139 135-145 mmol/L
Potassium 4.6 3.5-5.2 mmol/L
Creatinine 114 67-117 umol/L
Glomerular Filtration Rate (eGFR) 72 See below
Results rule out CKD stage 3-5. Assessment of
urine ACR is required to definitively rule out or
confirm CKD diagnosis. The KidneyWise toolkit
([Link]) recommends remeasuring eGFR
and urine ACR annually for people with diabetes
mellitus and less frequently in others unless
clinical circumstances dictate otherwise.\.sp\
Reference interval: =>60 mL/min/1.73m2
eGFR is calculated using the CKD-EPI 2021
equation which does not use a race-based
adjustment.
Bilirubin Total 8 <20 umol/L
Alkaline Phosphatase 70 40-129 U/L
Alanine Aminotransferase 38 <50 U/L
Lab - 5407: KENNEDY, 6560 Kennedy Road, Mississauga, Ontario.
Lab - 5687: LifeLabs, 100 International Blvd., Toronto, Ontario.
Page 2 of 3
PARTIAL RESULTS
IMPORTANT: This report contains confidential information intended for view by authorized person(s) only and should be
disposed of securely (e.g. shredding) before discarding.
Note to Health Care Providers: This report has been printed by the patient.
Note to patients: Please contact your Health Care Provider if you have any questions regarding the results on this report.
Patient: BILAL, MUHAMMAD SAQIB Lab No: 2026-6B7181458
Reference #:
Age: 40 years Sex: M Patient ID: 20266B7181458
Date of Birth: Dec 04 1985 Referring Site ID:
Address: 100 International Blvd.
HC #: 3072320983 HG Toronto, Ontario
Canada M9W 6J6
Patient's Phone: (647) 864-1186 Date of Service: Apr 28 2026 14:20
Telephone: (877) 849-3637
Reported on: Apr 29 2026 07:03 Toll Free: (877) 849-3637
Ordered by: PARVEEN DR. SAYEMA Fax: (905) 795-9891
Copy To:
Test Flag Result Reference Range - Units Lab Lic. #
Lipids
Hours After Meal 17 Hours
Triglyceride HI 1.72 mmol/L
FASTING: <1.70 mmol/L
NON-FASTING: <2.00 mmol/L
Cholesterol HI 5.70 <5.20 mmol/L
Total cholesterol and HDL-C used for risk
assessment and to calculate non HDL-C.
HDL Cholesterol LO 0.98 >=1.00 mmol/L
HDL-C <1.00 mmol/L indicates risk for metabolic
syndrome.
Non HDL Cholesterol HI 4.72 <4.20 mmol/L
Non HDL-Cholesterol is not affected by the
fasting status of the patient.\.sp\
If non-HDL-C >=4.20 mmol/L in primary prevention
setting for low risk patients (FRS 5-9.9%) or
intermediate risk patients (FRS 10-20%), consider
therapy. Therapy also suggested in low risk
patients (FRS <10%) with non-HDL-C >=5.8 mmol/L.
LDL Cholesterol HI 4.00 <3.50 mmol/L
If LDL-C >=3.50 mmol/L in primary prevention
setting for low risk patients (FRS 5-9.9%) or
intermediate risk patients (FRS 10-20%), consider
therapy. Therapy also suggested in low risk
patients (FRS <10%) with LDL-C >4.99 mmol/L.\.sp\LDL-C is calculated
using the NIH equation.
For additional LDL-C and non-HDL-C thresholds
based on risk stratification, refer to 2021 CCS
Guidelines. Can J Cardiol. 2021;37(8):1129-1150.
Cholesterol/HDL Ratio 5.8
Cholesterol/HDL-C is not included in the 2021 CCS
guideline as a lipid initiation or treatment
target but is recognized as an indicator of high
CVD risk at Cholesterol/HDL-C ratio >6.0
Thyroid Function
Thyroid Stimulating Hormone 1.54 0.32-4.00 mIU/L
Lab - 5407: KENNEDY, 6560 Kennedy Road, Mississauga, Ontario.
Lab - 5687: LifeLabs, 100 International Blvd., Toronto, Ontario.
Page 3 of 3
PARTIAL RESULTS
IMPORTANT: This report contains confidential information intended for view by authorized person(s) only and should be
disposed of securely (e.g. shredding) before discarding.
Note to Health Care Providers: This report has been printed by the patient.
Note to patients: Please contact your Health Care Provider if you have any questions regarding the results on this report.